Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study

BACKGROUND: Chronotherapy is an innovative approach to improving survival through timed delivery of anti-cancer treatments according to patient daily rhythms. Temozolomide (TMZ) is a standard-of-care chemotherapeutic agent for glioblastoma (GBM). Whether timing of TMZ administration affects GBM pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Damato, Anna R, Luo, Jingqin, Katumba, Ruth G N, Talcott, Grayson R, Rubin, Joshua B, Herzog, Erik D, Campian, Jian L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086242/
https://www.ncbi.nlm.nih.gov/pubmed/33959716
http://dx.doi.org/10.1093/noajnl/vdab041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086242/
https://www.ncbi.nlm.nih.gov/pubmed/33959716
http://dx.doi.org/10.1093/noajnl/vdab041

Ejemplares similares